Download your free iOS app to support optimized use and aids in the result interpretation of the VIDAS Emergency & Critical Care assays.

 

Save time when every minute counts: all the information you need for confident clinical decision- making with the VIDAS® Emergency & Critical Care assays.

Designed for healthcare professionals, MYACUTECASE™ is a first-of-its-kind app. Used in conjunction with clinical assessment and other laboratory findings, it provides comprehensive biomarker information and useful tools for:

Rapid diagnosis: rule-out or rule-in of heart failure and acute myocardial infarction

Early detection of sepsis, monitoring of patient response to therapy, and safe discontinuation of antibiotics

Safe exclusion of suspected pulmonary embolism / deep vein thrombosis in patients with low/intermediate or unlikely pre-test probability

Based on your choice of pre-test probability scoring and/or validated clinical decision trees, MYACUTECASE™ aids in the result interpretation of the VIDAS® Emergency & Critical Care assays, automatically suggests and reminds you of the next steps in the diagnostic process and provides recommendations for treatment.

MYACUTECASE™ is an IVD product, based on international literature, guidelines and expert recommendations. It’s compliant with the intended use of the VIDAS® Emergency & Critical Care assays (VIDAS® B·R·A·H·M·S PCT™, VIDAS® D-Dimer Exclusion™ II, VIDAS® NT-proBNP2, VIDAS® High sensitive Troponin I).

 

Features

Intuitive and easy navigation
  • Manage your case
  • Obtain assay information
Decision-support tool
  • Aid in result interpretation of VIDAS® assays using validated decision trees and test-specific cut-offs
  • Patient management recommendations based on validated instructions for use for assays
Patient management tool
  • Pre-test probability scoring
  • Choice of different scoring systems
  • On-demand storage of patient case
Patient Follow Up
  • Notifications for follow-up testing / serial measurements
  • Monitoring of PCT results for guided antibiotic therapy
Comprehensive high-value medical information on 4 key biomarkers in emergency and critical care settings: PCT, D-dimer, NT-proBNP, high-sensitivity cardiac troponin I
  • Clinical utility
  • International guidelines for use
  • Expert recommendations

Testimonial

 
Pr. Yann-Erick Claessens, Monaco
 
 

Education Videos

The Value of Emergency Biomarkers

How do emergency physicians secure their decisions when they only have 7 minutes per patient?

In this first video, Professor Yann-Erick Claessens, Head of the Emergency Department at Princess Grace Hospital in Monaco, explains how D-dimer, procalcitonin (PCT), NT-proBNP and high-sensitivity cardiac troponin I are used to safely rule in or rule out a diagnostic hypothesis, support efficient triage and optimize patient care.

Procalcitonin (PCT) in the diagnosis and management of lower respiratory tract infection (LRTI)

Discover with Professor Yann-Erick Claessens, Head of the Emergency Department at Princess Grace Hospital in Monaco:

  • How PCT informs clinicians on the likelihood of bacterial infection
  • How PCT can be used to guide decisions on antibiotic therapy in order to decrease antibiotic consumption, improve patient outcomes and reduce hospital costs
  • How using PCT to guide treatment decisions helps decrease the use of antibiotics and improve patient outcomes while reducing hospital costs

When pulmonary embolism (PE) is suspected, how does D-dimer help?

In this video, Professor Yann-Erick Claessens, Head of the Emergency Department at Princess Grace Hospital in Monaco, highlights the particular clinical value of D-Dimer as a safe and cost-effective exclusion test in patients with a low/intermediate or unlikely pre-test probability for PE.

High-sensitive cardiac Troponin I in acute myocardial infarction (AMI)

Professor Yann-Erick Claessens explains how High-sensitive cardiac Troponin I helps classify 70% of suspected acute myocardial infarction patients within 2 hours, decrease cardiac stress testing, discharge patients earlier from the ED and reduce global hospital costs.

How to use NT-proBNP to improve the diagnosis of acute heart failure

Professor Yann-Erick Claessens, Head of the Emergency Department at Princess Grace Hospital in Monaco, highlights the value of NT-proBNP in early identification of acute heart failure to improve patient outcomes and save hospital resources.

NT-proBNP in heart failure management

Are you an Emergency Physician?

Prof. Meune shows how NT-proBNP can be used in combination with echocardiography for diagnostic and prognostic purposes and to guide therapy. He also highlights the differences between NT-proBNP and BNP.

NT-proBNP in heart failure management

Are you a General Practitioner?

Prof. Meune shows how NT-proBNP can be used in combination with echocardiography for diagnostic and prognostic purposes and to guide therapy. He also highlights the differences between NT-proBNP and BNP.

NT-proBNP in heart failure management

Are you a Cardiologist?

Prof. Meune shows how NT-proBNP can be used in combination with echocardiography for diagnostic and prognostic purposes and to guide therapy. He also highlights the differences between NT-proBNP and BNP.

NT-proBNP in heart failure management

Are you a Biologist?

Prof. Meune shows how NT-proBNP can be used in combination with echocardiography for diagnostic and prognostic purposes and to guide therapy. He also highlights the differences between NT-proBNP and BNP.

Clinical Booklets

The information in these booklets is for educational purposes only and is not intended to be exhaustive. It is not intended to be a substitute for professional medical advice. Always consult a medical director, physician, or other qualified health provider regarding processes and/or protocols for diagnosis and treatment of a medical condition. bioMérieux assumes no responsibility or liability for any diagnosis established or treatment prescribed by the physician.

Contact Us

Fill in the form to be contacted by your bioMérieux representative


By submitting this form, you agree to the processing of your personal data in accordance with our Privacy Statement.